Contract Pharma Manufacturing News

  1. Evonik And Ethris Enter Strategic Partnership To Expand Offerings For Nucleic Acid Delivery 9/9/2025

    Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, have entered into a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery.

  2. ScaleReady Awards G-Rex® Grants To Support Cell And Gene Therapy Manufacturing In California 9/9/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network (INFR5) program.

  3. Matica Biotechnology And Cirsium Biosciences Announce AAV Manufacturing Collaboration 9/8/2025

    Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, and Cirsium Biosciences ("Cirsium"), a biotechnology company developing a breakthrough plant-based AAV (adeno-associated virus) technology, today announced a non-exclusive strategic partnership.

  4. Made Scientific And Hemogenyx Pharmaceuticals Announce Technology Transfer And Manufacturing Partnership To Advance HG-CT-1, An Autologous CAR-T Cell Therapy For Acute Myeloid Leukemia 9/8/2025

    Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases, today announced a manufacturing partnership to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in adults.

  5. Zydus And Synthon Entered Into Exclusive Licensing And Supply Agreement For Ozanimod Capsules (Generic Version Of ZEPOSIA®) For The U.S. Market 9/4/2025

    Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.

  6. Grünenthal PRO Is Joining SHL Medical's Alliance Partnership Network To Offer Final Assembly Service For Molly® Autoinjectors 9/4/2025

    Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector.

  7. Herma US To Exhibit Robotic Labeling Cell And Front/Back/Wrap Labeling Systems At Pack Expo 2025 9/3/2025
  8. Andelyn Biosciences And Tern Therapeutics Partner For Late-Stage Process Performance Qualification (PPQ) Manufacturing Of AAV Gene Therapy For The Treatment Of CLN2 Batten Disease 9/3/2025

    Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Tern Therapeutics (Tern) to perform late-stage Process Performance Qualification (PPQ) manufacturing of Tern's TTX-381 program.

  9. BioFactura Launches Capitol Biologics - New CDMO Division To Accelerate Biologics Development From Concept To Clinic 9/3/2025

    BioFactura, Inc., a clinical‑stage biopharmaceutical company specializing in high‑value biosimilars and critical biodefense medical countermeasures, today announced the formation of Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division dedicated to supporting the process development, early‑phase clinical manufacturing, and analytical needs of emerging biotechnology companies and U.S. government agencies.

  10. CDMO Grand River Aseptic Manufacturing Announces Denis Johnson As New CEO 9/2/2025

    Grand River Aseptic Manufacturing (“GRAM” or the “Company”), a portfolio company of Arlington Capital Partners, today announced the promotion of Denis Johnson to Chief Executive Officer, effective September 1, 2025. Mr. Johnson has served as President of GRAM since March 31, 2025.